Pyxis Oncology Inc. (NASDAQ:PYXS) on Wednesday shared updated data from its Phase 1 trial evaluating micvotabart pelidotin (MICVO).
The ongoing global study tested the drug as a monotherapy for patients facing second-line and beyond recurrent or metastatic head and neck squamous cell carcinoma.
Promising Efficacy And Safety Profile
The data showed rapid and deep responses in 33 evaluable patients receiving 5.4 mg/kg of MICVO intravenously every three weeks. The treatment achieved a 36% confirmed objective response rate and a 94% disease control rate.
Patients experienced a median progression-free survival of 6.2 months. Researchers have not yet reached the median overall survival, but the 12-month probability stands at 79%.
